Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can everyday drugs shield the liver from Cirrhosis's worst threats?

NCT ID NCT05511766

Prevention Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This clinical trial investigates whether two existing medications, allopurinol and atorvastatin, can help prevent serious complications in people with stable liver cirrhosis. The study will compare these drugs against a placebo to see if they reduce the number of acute decompensation events—such as fluid accumulation, bleeding, or infections—and improve survival and quality of life. Adults aged 18 to 75 with stable cirrhosis are eligible to participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allopurinol and atorvastatin
What this could lead to
If effective, these common drugs could offer a new way to prevent serious complications of liver cirrhosis, such as fluid buildup, bleeding, and infections, potentially improving survival and quality of life.
What could go wrong
This is an early-stage trial, and the drugs may not reduce complications as hoped. Both medications have potential side effects, and results may not apply to all cirrhosis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

150 people

The number who actually took part.

Started

Nov 2022

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria * Age 18 to 75 years old * Both sex * Adults with cirrhosis in a stable conditions Exclusion Criteria: * Exclusion criteria * Active SBP * Renal insufficiency (serum creatinine \> 2.0 mg/dl) * Active GIT hemorrhage

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ascites are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ascites cirrhosis of liver Fibrosis hepatic encephalopathy varicose disease hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ascites Cirrhosis Hepatic encephalopathy SBP - spontaneous bacterial peritonitis Varices

Contacts and locations

Locations

  • Tanta University

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.